论文部分内容阅读
目的探讨左乙拉西坦对原发性癫患儿血清超敏C反应蛋白(hs-CRP)和S100B蛋白的影响,为临床合理用药提供理论依据。方法选取符合标准的患儿60例,随机分为对照组和观察组各30例,对照组给予丙戊酸钠治疗,观察组应用左乙拉西坦治疗,治疗6个月评价临床疗效,并比较治疗前及治疗6个月后患儿血清hs-CRP和S100B蛋白水平。结果治疗6个月后,观察组患儿总有效率为93.33%,对照组为70.00%,二者比较差异有统计学意义(P<0.05);治疗6个月后,二组患儿血清hs-CRP和S100B蛋白水平与治疗前比较均下降,差异有统计学意义(P<0.05);但是观察组比对照组下降幅度更大,差异有统计学意义(P<0.05)。结论左乙拉西坦治疗儿童原发性癫具有较好的临床疗效,可能与降低血清中hs-CRP和S100B蛋白的表达有关。
Objective To investigate the effect of levetiracetam on serum hs-CRP and S100B protein in children with primary epilepsy and to provide a theoretical basis for clinical rational drug use. Methods Sixty children with standard criteria were randomly divided into control group and observation group, 30 cases in each group. The control group was treated with sodium valproate. The observation group was treated with levetiracetam. The clinical efficacy was evaluated 6 months after treatment Serum levels of hs-CRP and S100B were compared before treatment and 6 months after treatment. Results After 6 months of treatment, the total effective rate was 93.33% in the observation group and 70.00% in the control group, the difference was statistically significant (P <0.05); after 6 months of treatment, the serum hs The levels of -CRP and S100B protein decreased compared with those before treatment (P <0.05). However, the observation group had a more significant decrease than the control group (P <0.05). Conclusion Levetiracetam has good clinical efficacy in treating children with primary epilepsy, which may be related to the decrease of serum hs-CRP and S100B protein expression.